Mucopolysaccharidosis Treatment companies

Key Mucopolysaccharidosis (MPS) Treatment Market Players:

The international mucopolysaccharidosis (MPS) treatment market is an oligopoly, which is readily dominated by innovative biotechs and specialized pharmaceutical giants. Besides, notable strategic initiatives include relentless research and development (R&D) funding in cutting-edge therapies, including CNS-penetrant ERTs and gene therapy, with the intention to cater to increased demand for neurological symptoms. Meanwhile, organizations are strongly pursuing orphan drug designations for premium pricing and market exclusivity; for instance, Takeda and BioMarin have leveraged their respective established commercial facilities for worldwide launches, thereby proliferating the mucopolysaccharidosis (MPS) treatment market globally.

Here is a list of key players operating in the global market:

• BioMarin Pharmaceutical Inc. (U.S.)
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Sanofi (France)
• Regenxbio Inc. (U.S.)
• UCB S.A. (Belgium)
• Inventiva Pharma (France)
• ArmaGen, Inc. (U.S.)
• Denali Therapeutics Inc. (U.S.)
• Sangamo Therapeutics, Inc. (U.S.)
• Abeona Therapeutics Inc. (U.S.)
• Green Cross Corp. (South Korea)
• GC Pharma (South Korea)
• Amicus Therapeutics, Inc. (U.S.)
• M6P Therapeutics (U.S.)
• Passage Bio, Inc. (U.S.)
• Sarepta Therapeutics, Inc. (U.S.)